uniQure
Meibergdreef 61
Amsterdam
1105 BA
Tel: 31-20-566-7394
Fax: 31-20-566-9272
Website: http://www.uniqure.com/
Email: info@uniQure.com
163 articles with uniQure
-
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 11, 2022
5/11/2022
uniQure N.V. announced that the Company granted equity awards to 32 newly hired employees as a material inducement to commencing their employment.
-
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
5/2/2022
uniQure N.V. announced that six data presentations, including one oral presentation, will be delivered at the American Society of Gene and Cell Therapy Hybrid Congress 2022 Annual Meeting being held May 16-19 in Washington, D.C.
-
uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
5/2/2022
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2022 and highlighted recent progress across its business.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
uniQure Announces 2021 Financial Results and Highlights Recent Company Progress
2/25/2022
uniQure N.V. today reported its financial results for 2021 and highlighted recent progress across its business.
-
Three genome editing companies, Intellia Therapeutics, Editas Medicine and uniQure, are each anticipating a bright 2022 as the promises of gene therapy continue to be realized.
-
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
2/7/2022
uniQure N.V. today announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
12/16/2021
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced initial observations on the first four patients enrolled in the lower-dose cohort of its ongoing Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
12/9/2021
Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single dose of etranacogene dezaparvovec.
-
CSL Behring and uniQure announced that their etranacogene dezaparvovec hit the pre-specified primary endpoint in their Phase III clinical trial in severe to moderately severe hemophilia B.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
11/2/2021
uniQure N.V. today announced the positive recommendation by the independent Data Safety Monitoring Board (DSMB) following a review of safety data from the four patient procedures in the higher-dose cohort of the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.
-
uniQure to Participate in Upcoming Industry Conferences in November
11/1/2021
uniQure N.V. today announced its participation in the following upcoming investor and scientific conferences: The 28th Annual Meeting of the Huntington Study Group (Virtual), November 4 - 6, 2021
-
uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
10/21/2021
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the appointment of Rachelle Jacques to its Board of Directors.
-
uniQure to Participate in Multiple Upcoming Industry Conferences in October
9/30/2021
uniQure N.V. today announced its participation in the following upcoming investor and scientific conferences: Chardan’s 5th Annual Genetic Medicines Conference, October 4 - 5, 2021
-
uniQure to Participate in Multiple Upcoming Industry Conferences in September 2021
9/7/2021
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced its participation in the following upcoming investor and scientific conferences.
-
The oncogenicity and neurotoxicity risks of AAVs and possible mitigation strategies were the primary focus on Thursday.
-
uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
8/30/2021
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that two additional patient procedures have been completed in the second, higher-dose cohort in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.